Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: A population-based study

Neuropathology

Volumn 31, Issue 6, 2011, Pages 583-588

  Nobusawa, Sumihito ^a,b   Stawski, Robert ^a   Kim, Young Ho ^a   Nakazato, Yoichi ^b   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

4q12; Glioblastoma; KDR; KIT; PDGFRA; Population based study

Indexed keywords

TYROSINE KINASE RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CHROMOSOME 4Q; CONTROLLED STUDY; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; SCREENING;

BRAIN NEOPLASMS; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 82055172270     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2011.01204.x     Document Type: Article

References (33)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
2. Ohgaki H, Dessen P, Jourde B etal. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
3. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453.
4. Homma T, Fukushima T, Vaccarella S etal. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropatho Exp Neurol 2006; 65: 846-854.
5. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-6007.
6. Nobusawa S, Lachuer J, Wierinckx A etal. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol 2010; 20: 936-944.
7. Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, von DA. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol 2007; 9: 291-297.
8. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ. A survey of glioblastoma genomic amplifications and deletions. J Neurooncol 2010; 96: 169-179.
9. Fleming TP, Saxena A, Clark WC etal. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550-4553.
10. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005; 207: 224-231.
11. Puputti M, Tynninen O, Sihto H etal. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 2006; 4: 927-934.
12. Rollbrocker B, Waha A, Louis DN, Wiestler OD, von Deimling A. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol 1996; 92: 70-74.
13. Tohma Y, Gratas C, Biernat W etal. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57: 684-689.
14. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161-173.
15. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-5557.
16. Pringle N, Collarini EJ, Mosley MJ, Heldin CH, Westermark B, Richardson WD. PDGF A chain homodimers drive proliferation of bipotential (O-2A) glial progenitor cells in the developing rat optic nerve. EMBO J 1989; 8: 1049-1056.
17. McKinnon RD, Waldron S, Kiel ME. PDGF alpha-receptor signal strength controls an RTK rheostat that integrates phosphoinositol 3'-kinase and phospholipase Cgamma pathways during oligodendrocyte maturation. J Neurosci 2005; 25: 3499-3508.
18. Ida JA, Jr, Dubois-Dalcq M, McKinnon RD. Expression of the receptor tyrosine kinase c-kit in oligodendrocyte progenitor cells. J Neurosci Res 1993; 36: 596-606.
19. Jin X, Han CS, Yu FQ, Wei P, Hu ZY, Liu YX. Anti-apoptotic action of stem cell factor on oocytes in primordial follicles and its signal transduction. Mol Reprod Dev 2005; 70: 82-90.
20. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-865.
21. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004; 66: 129-138.
22. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005; 16: 1702-1708.
23. Reardon DA, Egorin MJ, Quinn JA etal. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23: 9359-9368.
24. Rich JN, Reardon DA, Peery T etal. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22: 133-142.
25. Hermanson M, Funa K, Koopmann J etal. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 1996; 56: 164-171.
26. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
27. Hermanson M, Funa K, Hartman M etal. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-3219.
28. Nister M, Libermann TA, Betsholtz C etal. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988; 48: 3910-3918.
29. Eoli M, Menghi F, Bruzzone MG etal. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007; 13: 2606-2613.
30. Harada K, Kurisu K, Tahara H, Tahara E, Ide T, Tahara E. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg 2000; 93: 618-625.
31. Kleihues P, Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol Pathol 2000; 28: 164-170.
32. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361: 323-331.
33. Verhaak RG, Hoadley KA, Purdom E etal. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.